AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca plans quick-fire $3.5bn US investment
AstraZeneca PLC (LSE:AZN) has announced a $3.5 billion investment to expand its research and manufacturing operations in the United States by 2026, with $2 billion allocated to creating more than 1,000 high-skilled jobs. AZ said the expansion is the first step in its 'Ambition 2030' plan, through which it aims to reach $80 billion in total revenue by 2030.
AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time in less than four months on Tuesday, helped by resilient demand for its cancer and rare diseases medicines, after third-quarter results beat estimates.
AstraZeneca, Vodafone, Shell court ruling set the stage for busy Tuesday
A busy Tuesday will see AstraZeneca, Vodafone and Flutter all report, while UK unemployment figures and Shell's court ruling in the Netherlands will also be in focus.
ATTENTION AstraZeneca PLC Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here's how Americans voted on abortion access.
AZN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AstraZeneca PLC
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
AstraZeneca has explaining to do after £50 billion value hit
At the start of September when its share price was at an all-time high and it was comfortably the UK's largest company, AstraZeneca PLC (LSE:AZN) management might have been expecting a routine third-quarter update. Two months on however and £50 billion has been wiped from its value with growing questions over its pipeline and operation in China.
AstraZeneca hails positive phase III data for repurposed asthma treatment
AstraZeneca PLC (LSE:AZN) and Amgen Inc (NASDAQ:AMGN, ETR:AMG) have unviled positive results from their phase III WAYPOINT study, which tested the effectiveness of Tezspire (tezepelumab) in treating chronic rhinosinusitis with nasal polyps. The research found the drug, currently used to treat severe asthma, significantly reduced the size of nasal polyps and decreased nasal congestion compared to a placebo.
Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing
Astrazeneca (AZN) reachead $64.69 at the closing of the latest trading day, reflecting a +1.32% change compared to its last close.
ATTENTION AZN SHAREHOLDERS: Investors who lost money on AstraZeneca PLC are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)
AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy the stock as the big picture looks positive. The company's numbers were strong in H1 2024 and its earnings release for Q3 2024 is expected to continue reflecting financial healthy. The combination of a positive outlook for 2024 and the latest price drop also makes the forward P/E attractive.
